Last10K.com

Actinium Pharmaceuticals, Inc. (ATNM) SEC Filing 10-K Annual report for the fiscal year ending Saturday, December 31, 2016

Actinium Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1388320 Ticker: ATNM
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2016
Mar. 16, 2017
Jun. 30, 2016
Document and Entity Information [Abstract]   
Entity Registrant NameActinium Pharmaceuticals, Inc.  
Entity Central Index Key0001388320  
Amendment Flagfalse  
Current Fiscal Year End Date--12-31  
Document Type10-K  
Document Period End DateDec. 31, 2016  
Document Fiscal Year Focus2016  
Document Fiscal Period FocusFY  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Filer CategoryAccelerated Filer  
Entity Public Float  $ 80,515,360
Entity Common Stock, Shares Outstanding 55,807,742 

View differences made from one year to another to evaluate Actinium Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Actinium Pharmaceuticals, Inc..

Continue

Assess how Actinium Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Actinium Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statement Of Changes In Stockholders' Equity (deficit)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Commitments And Contingencies
Commitments And Contingencies (details 1)
Commitments And Contingencies (details Textual)
Commitments And Contingencies (details)
Commitments And Contingencies (tables)
Derivatives
Derivatives (details 1)
Derivatives (details Textual)
Derivatives (details)
Derivatives (tables)
Description Of Business And Summary Of Significant Accounting Policies
Description Of Business And Summary Of Significant Accounting Policies (details 1)
Description Of Business And Summary Of Significant Accounting Policies (details Textual)
Description Of Business And Summary Of Significant Accounting Policies (details)
Description Of Business And Summary Of Significant Accounting Policies (policies)
Description Of Business And Summary Of Significant Accounting Policies (tables)
Equity
Equity (details Textual)
Equity (details)
Equity (tables)
Income Taxes
Income Taxes (details 1)
Income Taxes (details Textual)
Income Taxes (details)
Income Taxes (tables)
Note Payable
Note Payable (details)
Prepaid Expenses And Other Current Assets
Prepaid Expenses And Other Current Assets (details)
Prepaid Expenses And Other Current Assets (tables)
Property And Equipment
Property And Equipment (details Textual)
Property And Equipment (details)
Property And Equipment (tables)
Related Party Transactions
Related Party Transactions (details Textual)
Related Party Transactions (details)
Related Party Transactions (tables)
Subsequent Events
Subsequent Events (details)
Ticker: ATNM
CIK: 1388320
Form Type: 10-K Annual Report
Accession Number: 0001213900-17-002461
Submitted to the SEC: Thu Mar 16 2017 4:29:57 PM EST
Accepted by the SEC: Thu Mar 16 2017
Period: Saturday, December 31, 2016
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/atnm/0001213900-17-002461.htm